NewsStackNewsStack
Daily Brief: Which companies are hyping vs delivering: red flags, real signals and repeat offenders, free daily.

Hemogenyx Pharmaceuticals

LSE:HEMOLSE
3 announcements
Credibility Score63%
Hemogenyx Pharmaceuticals — First Patient Treated in Second Adult Dose Cohort
Overhypedunclear

Hemogenyx has begun treating the second cohort in its Phase I CAR-T trial at double dose.

12 Nov 2026, 07:00 UTC
▼
Hemogenyx Pharmaceuticals — Collaboration with Cellin Technologies
OverhypedModerate hypeunclear

Hemogenyx signs its first binding CAR-T therapy deal, but revenue remains months away.

11 Aug 2026, 06:05 UTC
▼
Collaboration and Company Update
OverhypedModerate hypeunclear

Hemogenyx signs a Lithuanian LOI, but all clinical and financial milestones remain unproven.

29 Jul 2026, 06:20 UTC
▼